openPR Logo
Press release

Investigation announced for Investors in Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares over possible Violations of Securities Laws

02-26-2020 05:32 PM CET | Politics, Law & Society

Press release from: Shareholders Foundation

An investigation for investors in Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares over potential securities laws violations.

An investigation for investors in Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares over potential securities laws violations.

An investigation was announced over potential securities laws violations by Adverum Biotechnologies, Inc. in connection with certain financial statements.

Investors who purchased shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Adverum Biotechnologies, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. ADVM-022 was intended to treat wet age-related macular degeneration ("wet AMD").
On September 12, 2019, Adverum Biotechnologies, Inc disclosed that patients taking the drug in the study suffered significant deterioration in their sight.

Shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) declined from $16.38 per share in July 2019 to as low as $5.10 per share in October 2019.

Those who purchased shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares over possible Violations of Securities Laws here

News-ID: 1946567 • Views: 244

More Releases from Shareholders Foundation

Investgiation for Long-Term NASDAQ: KINS Investors announced over possible Wrong …
An investigation on behalf of current long-term investors in shares of Kingstone Companies, Inc. (NASDAQ: KINS) was announced over potential breaches of fiduciary duties by certain officers and directors at Kingstone Companies, Inc. Investors who purchased shares of Kingstone Companies, Inc. (NASDAQ: KINS) and currently hold any of those Kingstone Companies, Inc. (NASDAQ: KINS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for NYSE:FCAU Investors announced over possible Wrongdoing at Fiat …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fiat Chrysler Automobiles N.V.. Investors who are current long term investors in Fiat Chrysler Automobiles N.V. (NYSE: FCAU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: FCAU stocks follows a lawsuit filed against Fiat
Investigation for Investors in shares of Domino's Pizza, Inc. (NYSE: DPZ) over p …
An investigation on behalf of current long-term investors in shares of Domino's Pizza, Inc. (NYSE: DPZ) was announced over potential breaches of fiduciary duties by certain officers and directors at Domino's Pizza, Inc. Investors who purchased shares of Domino's Pizza, Inc. (NYSE: DPZ) and currently hold any of those NYSE: DPZ shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by
Deadline Lawsuit for Investors in shares of CPI Aerostructures, Inc. (NYSE: CVU) …
The Shareholders Foundation announced that a deadline is coming up on April 24, 2020in the lawsuit filed for certain investors of CPI Aerostructures, Inc. (NYSE: CVU) over alleged securities laws violations by CPI Aerostructures, Inc. Investors who purchased shares of CPI Aerostructures, Inc. (NYSE: CVU) have certain options and there are strict and short deadlines running. Deadline: April 24, 2020. NYSE: CVU stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or

All 5 Releases


More Releases for Adverum

Hereditary Angioedema Market To Grow Like Never Before By 2026 With Key Players …
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel
Explore the latest developments in ATMPs at Cell & Gene Therapy 2018
SMi Group are delighted to welcome expertise from a senior panel of big pharma and biotech organisations and regulatory bodies, at the most talked about conference on Cell & Gene Therapy 2018 launching this October in the City of London, UK. Outstanding Speaker Line-up: The conference will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases, using gene delivery technology, stem cell manipulation
Friedreich Ataxia Global Key Players - Adverum Biotechnologies Inc, Biovista Inc …
Friedreich Ataxia Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes. Click here for sample report @ https://www.wiseguyreports.com/sample-request/3054160-friedreich-ataxia-pipeline-review-h1-2018   Major Key Players: Adverum Biotechnologies Inc Biovista Inc Catabasis Pharmaceuticals Inc Ixchel Pharma LLC Pfizer Inc Friedreich Ataxia Industry Major
Friedreich Ataxia Key Players - Adverum Biotechnologies Inc, Biovista Inc, and C …
Friedreich Ataxia Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes. Click here for sample report @ https://www.wiseguyreports.com/sample-request/3054160-friedreich-ataxia-pipeline-review-h1-2018   Major Key Players: Adverum Biotechnologies Inc Biovista Inc Catabasis Pharmaceuticals Inc Ixchel Pharma LLC Pfizer Inc Friedreich Ataxia Industry Major
Hereditary Angioedema Therapeutics Pipeline Drug Profile, Top Industry Intellige …
The pipeline of hereditary angioedema is increasing on account of rising instances of angioedema, globally. Currently, an estimated prevalence of hereditary angioedema in the world is 1 in 10,000 to 1 in 150,000. Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis Major factors driving the growth of pipeline for hereditary angioedema include increasing prevalence of attacks of angioedema and rising cases of angioedema in association with other conditions like significant hypotension resulting
Peanut Allergy Therapeutics Market Global Industry Analysis, Size, Share, Growth …
In this report, the Global Peanut Allergy Therapeutics Market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request for a Sample Report please visit @ https://www.qyresearchgroups.com/request-sample/652162 Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Peanut